Therion Biologics Corporation

Phase I study for antitumor CEA-TRICOM published

Published in Law and Health Weekly, January 22nd, 2005

Researchers led by John L. Marshall, MD of Georgetown University published the results of a phase I study demonstrating the safety and antitumor activity of Therion Biologics' CEA-TRICOM therapeutic cancer vaccine in the Journal of Clinical Oncology.

The phase I study evaluated multiple dosing regimens of the CEA-TRICOM vaccines in 58 patients with advanced CEA-expressing tumors. Investigators found that disease stabilization was achieved for at least 4 months in 40% of the study participants, and for more than 6 months in 24% of the participants.

One patient with small cell lung cancer achieved a complete response, with no evidence of cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-01-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry